QURE: Future Regulatory Clarity Will Drive Gene Therapy Upside Despite FDA Setback

The analyst price target for uniQure has been reduced from $56 to $38 as analysts factor in heightened regulatory uncertainty around AMT-130, a higher perceived discount rate, and more conservative revenue growth expectations, despite still-supportive long term Huntington's disease data.

Analyst Commentary

Analyst views on uniQure have shifted rapidly from optimism following the three year AMT 130 data to caution after the FDA withdrew support for a BLA based on the current Phase 1 2 package. This has driven a wide dispersion in price targets and ratings.

Bullish Takeaways

Bullish analysts still view AMT 130 as a leading Huntington's candidate, citing robust, durable slowing of disease progression that could ultimately justify meaningful premium pricing and category leadership.
Several models continue to assume a commercial launch around 2028. This suggests that, while timelines are pushed out, long term revenue potential for AMT 130 remains intact if regulatory hurdles are resolved.
Positive sentiment around Huntington's patient advocacy momentum and unmet need supports assumptions for strong initial uptake once clarity on approvability and labeling is restored.
Despite cuts, some price targets in the $45 to $53 range reflect confidence that improved trial design and additional data could restore a higher probability of success and re rate the shares from depressed levels.

Bearish Takeaways

Bearish analysts emphasize that the FDA's rejection of external control comparisons as a primary regulatory path introduces structural uncertainty. This has led to reduced probabilities of success and lower discounted cash flow valuations.
The loss of a near term BLA filing and delay of potential launch from 2026 to at least 2028 compress near to mid term revenue expectations and lengthen the period of cash burn, heightening financing and execution risk.
The roughly 50 percent share price decline following the FDA reversal is seen as justified by some, given concerns that management must now redesign or expand clinical development, adding time, cost, and operational complexity.
More cautious models also factor in a higher discount rate for the gene therapy portfolio overall, reflecting worries that shifting FDA standards on natural history controls may weigh on future programs beyond AMT 130.

What's in the News

William Blair downgraded uniQure to Market Perform from Outperform, reflecting increased regulatory uncertainty and a more cautious risk reward view (periodical).
Final FDA meeting minutes from the October 29, 2025 pre BLA meeting confirmed that Phase I II AMT 130 data are currently unlikely to provide primary evidence for a BLA. This is forcing uniQure to reassess its regulatory strategy and timelines (key development).
Preliminary FDA feedback at the same pre BLA meeting indicated the agency no longer supports reliance on external control comparisons as the main basis for AMT 130 approval. This is creating significant uncertainty around the timing and path of any BLA submission (key development).
uniQure completed a follow on equity offering of roughly $300 million in ordinary shares and pre funded warrants, bolstering its balance sheet ahead of potentially longer and more complex AMT 130 development (key development).
The company announced positive topline Phase I II data for AMT 130 showing statistically significant slowing of Huntington's disease progression versus an external control. This is underpinning investor debate over whether clinical strength can ultimately overcome regulatory hurdles (key development).

Valuation Changes

Fair Value: Model implied fair value per share has fallen slightly, moving from approximately 58.21 to 55.44.
Discount Rate: The assumed discount rate has risen modestly, from about 7.18 percent to 7.34 percent, reflecting higher perceived risk.
Revenue Growth: Long term revenue growth expectations have been reduced meaningfully, from roughly 170.46 percent to 158.12 percent.
Net Profit Margin: The projected net profit margin remains effectively unchanged, holding at around 16.03 percent.
Future P/E: The forward price to earnings multiple has increased from about 109.06 times to 120.01 times, indicating a higher valuation multiple on future earnings despite reduced growth assumptions.

Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment.
Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.
Reliance on AMT-130’s success and regulatory outcomes, amid revenue challenges and manufacturing changes, heightens exposure to product development and supply chain risks.

Catalysts

About uniQure

Develops treatments for patients suffering from rare and other devastating diseases in the United States.What are the underlying business or industry changes driving this perspective?

The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition.
Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.
The company’s strategic financial moves, including reducing cash burn and strengthening the balance sheet through a targeted offering, provide financial resilience and flexibility to support pipeline advancement and potentially improve net margins.
With strong cash reserves of over $400 million, uniQure is well-positioned to fund operations through the launch of AMT-130 and support other key data readouts, likely impacting earnings positively.
Impressive clinical results and newly granted breakthrough therapy designation for AMT-130 might enhance investor confidence, potentially driving stock value through anticipated increases in revenue and investor sentiment.

uniQure Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming uniQure's revenue will grow by 147.5% annually over the next 3 years.
Analysts are not forecasting that uniQure will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate uniQure's profit margin will increase from -1077.1% to the average US Biotechs industry of 10.5% in 3 years.
If uniQure's profit margin were to converge on the industry average, you could expect earnings to reach $32.3 million (and earnings per share of $0.48) by about July 2028, up from $-217.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $439.8 million in earnings, and the most bearish expecting $-242.8 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 90.8x on those 2028 earnings, up from -3.6x today. This future PE is greater than the current PE for the US Biotechs industry at 16.5x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.2%, as per the Simply Wall St company report.

uniQure Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The company's reliance on successful regulatory outcomes, specifically the BLA submission for AMT-130, coupled with uncertainties about FDA interactions and changes in FDA leadership, poses a risk that could impact revenue and projected market entry timelines.
The decrease in revenue from $8.5 million in Q1 2024 to $1.6 million in Q1 2025 highlights challenges in sustaining revenue streams, which may affect the company's short-term financial health.
The divestiture of the GMP manufacturing facility and reliance on external entities for manufacturing could impact cost efficiencies or lead to potential supply chain disruptions, affecting net margins.
The presence of serious adverse events related to immunosuppression in clinical trials indicates risks that may require additional resources to address or delay product timelines, potentially impacting future earnings.
The company's strong dependency on the success of AMT-130 and limited diversification of revenue-generating products increase their exposure to product development risks which might impact future revenue if any set targets are not met.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $35.514 for uniQure based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $69.56, and the most bearish reporting a price target of just $13.41.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $306.4 million, earnings will come to $32.3 million, and it would be trading on a PE ratio of 90.8x, assuming you use a discount rate of 7.2%.
Given the current share price of $14.25, the analyst price target of $35.51 is 59.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on uniQure?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake